Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Updates on Kate Middleton’s Cancer Journey

    September 16, 2024

    Healthcare communities unite at IHH Singapore Sea Regatta

    September 14, 2024

    Researchers Unveil Speech Clues to Dementia

    September 13, 2024
    Facebook Instagram YouTube TikTok
    Facebook Instagram YouTube TikTok
    Medical Channel Asia
    • Health Conditions
      • FEATURED
        • Men’s Health
        • Women’s Health
        • Sports & Fitness
        • Foot Health
        • Sleep
      • CATEGORIES
        • Alternative & Traditional Therapies
        • Cancer
        • Children’s Health
        • Dental Health
        • Diabetes
      •  
        • Ear, Nose & Throat (ENT)
        • Eyes
        • Foot Health
        • Men’s Health
        • Mental Health
      •  
        • Muscles & Joints
        • Nervous System
        • Skin
        • Sports
        • Thyroid Disease
        • Women’s Health
    • Events
    • Ask a Doctor
    • Visit A Doctor
    • HCP Login
    Medical Channel Asia
    Home»Access Only»Could An Epilepsy Drug Reverse Alzheimer’s Symptoms?
    Access Only

    Could An Epilepsy Drug Reverse Alzheimer’s Symptoms?

    Jacqueline ChinBy Jacqueline ChinJuly 9, 2024
    Share Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Recent advances reveal that an epilepsy drug may reverse Alzheimer’s symptoms, paving the way for innovative dementia treatments.

    Global Impact of Dementia and Alzheimer’s Disease

    The prevalence of dementia, a complex condition characterised by a decline in cognitive functions, is rising globally, affecting approximately 55 million people. Common symptoms of dementia include memory loss, impaired thinking skills, reduced judgement and reasoning capabilities, decreased focus and attention, language difficulties, and behavioural changes. Alzheimer’s disease, the most prevalent form of dementia, accounts for 60-70% of these cases. The situation is particularly pronounced in Asia due to rapidly ageing populations, especially in countries like Japan, China, and South Korea. It is estimated that by 2050, nearly 23 million people in Asia will be living with Alzheimer’s disease, reflecting broader global trends in ageing demographics and the rising incidence of this neurodegenerative disease. This highlights the urgent need for enhanced healthcare strategies and scientific advancements. In this article, we delve into the current treatment landscape, including current management approaches and recent scientific breakthroughs.

    Current Treatment Landscape for Alzheimer’s Disease

    Current treatments for Alzheimer’s disease primarily address symptoms. Cholinesterase inhibitors and memantine (Namenda) are commonly used to enhance neurotransmitter function and mitigate memory loss and cognitive decline. However, these therapies do not stop the progression of neuron degeneration, which remains a significant factor in Alzheimer’s development.

    Innovative Therapeutic Strategies on the Horizon

    Emerging strategies in Alzheimer’s treatment are increasingly focusing on the molecular underpinnings of the disease, with several promising avenues under investigation:

    Targeting Amyloid Plaques

    Monoclonal antibodies like lecanemab and donanemab are being studied for their ability to target and facilitate the clearance of amyloid plaques from the brain, potentially slowing cognitive decline. Lecanemab, specifically, has received FDA approval for treatment in early stages following promising clinical trial results. However, lecanemab carries potential risks, including rare instances of brain swelling and bleeding. This necessitates careful evaluation of the benefits against the risks, particularly for individuals already at elevated risk for Alzheimer’s disease.

    Beta-Amyloid Production Inhibition

    Beta- and gamma-secretase inhibitors aim at reducing beta-amyloid formation. However, these have had limited success in slowing cognitive decline and have caused significant side effects in mild to moderate Alzheimer’s cases, dampening enthusiasm for these treatments.

    Neuronal Protection Strategies

    Saracatinib, initially developed for cancer, is now being tested for Alzheimer’s disease. It has shown potential in preclinical studies by reactivating synapses and reversing memory loss, with human trials underway.

    Tau Protein Inhibitors

    With the goal of preventing the formation of tau tangles, another pathological hallmark of Alzheimer’s, tau aggregation inhibitors and vaccines are currently undergoing clinical trials.

    Anti-inflammatory Approaches

    Given the chronic low-level inflammation observed in Alzheimer’s, treatments like sargramostim are being explored to modulate the immune response and protect against inflammation-induced neuronal damage.

    Metabolic and Cardiovascular Linkages

    Research indicates a strong connection between brain health and cardiovascular health, prompting ongoing investigations into how metabolic and cardiovascular conditions impact Alzheimer’s disease. Studies are exploring whether medications currently used to treat heart disease and diabetes might also reduce the risk or slow the progression of dementia.

    Hormonal and Lifestyle Factors

    The interplay between lifestyle choices, hormonal changes, and Alzheimer’s risk is also a significant area of research, highlighting the potential of non-pharmacological interventions to delay disease onset, including exercise and diet. Researchers are also investigating the potential of treatments targeting insulin signalling pathways.

    Breakthroughs in Molecular Targeting of Alzheimer’s

    These strategies mentioned above not only represent the forefront of Alzheimer’s research but also offer hope for more effective treatments that target the disease’s root causes rather than merely managing symptoms. In recent research led by Li-Huei Tsai at MIT’s Picower Institute for Learning and Memory, the team explored the therapeutic potential of an epilepsy drug and a peptide for treating Alzheimer’s disease. Here is a breakdown of the studies:

    Results

    Amyloid beta plaques, which are linked to Alzheimer’s symptoms, are densely packed in certain areas. These brain areas are particularly prone to hyperactivity and degeneration which are associated with memory impairments in mice. Experimental treatments with the epileptic drug, levetiracetam, reverses memory impairments, and treatments with a peptide significantly reduced DNA damage, neural inflammation, and neuron loss in Alzheimer’s disease mice models.

    Mechanism

    The peptide drug inhibits an overactive enzyme known as CDK5. CDK5, a protein involved in neuronal functions, is usually activated by another protein called P35. In Alzheimer’s, P35 degrades into a smaller form, P25, causing CDK5 to incorrectly phosphorylate Tau proteins, thus forming damaging Tau tangles.

    Innovation

    Traditional drugs targeting P25 inadvertently disrupted other crucial enzymes, causing undesirable effects. The MIT team pioneered a selective approach using a peptide that mirrors a specific segment of CDK5, effectively blocking its harmful interaction with P25.

    Impact

    This targeted intervention holds the potential to alleviate or prevent the progression of Alzheimer’s disease by interrupting a key pathological process without affecting other cellular functions, offering a promising avenue for therapeutic development.

    Conclusion

    In conclusion, with dementia affecting approximately 55 million people worldwide, the urgency for advanced treatments is evident. Existing treatments, such as cholinesterase inhibitors and memantine, primarily offer symptomatic relief for Alzheimer’s disease. Yet, promising developments, including monoclonal antibodies and innovative treatments like saracatinib, are emerging. A breakthrough at MIT’s Picower Institute with a peptide that inhibits CDK5 could significantly alter Alzheimer’s pathology by reducing neuron loss and inflammation. The future of Alzheimer’s treatment likely involves a multifaceted approach, akin to strategies used in cancer or HIV treatment. Initiatives like the Critical Path for Alzheimer’s Disease (CPAD) consortium are pivotal. It enhances research through collaboration and data sharing to accelerate clinical applications. As of 2020, CPAD’s database (https://codr.c-path.org/) already contains 41 studies. These advancements signal a shift towards more effective therapies, potentially transforming the management of neurodegenerative diseases and offering new hope to millions worldwide.

    References

    1. World Health Organization. (2023, March 15). Dementia. https://www.who.int/news-room/fact-sheets/detail/dementia
    2. The Lancet Neurology. (2015). Dementia warning for the Asia-Pacific region. The Lancet Neurology, 14(1), 1. https://doi.org/10.1016/S1474-4422(14)70312-6
    3. Mayo Clinic Staff. (2024, February 13). Alzheimer’s treatments: What’s on the horizon? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimers-treatments/art-20047780
    4. Huang, W.-C., Peng, Z., Murdock, M. H., Liu, L., Mathys, H., Davila-Velderrain, J., Jiang, X., Chen, M., Ng, A. P., Kim, T., Abdurrob, F., Gao, F., Bennett, D. A., Kellis, M., & Tsai, L.-H. (2023). Lateral mammillary body neurons in mouse brain are disproportionately vulnerable in Alzheimer’s disease. Science Translational Medicine, 15, eabq1019. https://doi.org/10.1126/scitranslmed.abq1019

    Pao, P.-C., Seo, J., Lee, A., Kritskiy, O., Patnaik, D., Penney, J., Raju, R. M., Geigenmuller, U., Silva, M. C., Lucente, D. E., Gusella, J. F., Dickerson, B. C., Loon, A., Yu, M. X., Bula, M., Yu, M., Haggarty, S. J., & Tsai, L.-H. (2023). A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes. Proceedings of the National Academy of Sciences, 120(16), e2217864120. https://doi.org/10.1073/pnas.2217864120

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Jacqueline Chin

    Jacqueline is a multidisciplinary scientist with extensive experience in conducting research and data analysis. She is also an avid reader and writer who aims to craft articles that inform, engage, and impact her community.

    Related Posts

    Access Only

    Researchers Unveil Speech Clues to Dementia

    September 13, 2024
    Access Only

    The Impact of Parental Technology Use on Child Development

    September 9, 2024
    Access Only

    GPT-4 vs. Human Expertise in Radiology

    August 28, 2024
    Baby Health

    DOH Emphasises Breastfeeding for Newborns as a Shield Against Diarrhoea and Infections

    August 28, 2024
    Elderly Health

    How a High Fruit Intake Might Combat Depression and TCM’s Take

    August 27, 2024
    Access Only

    Pregnant Women Face Increased Vulnerability and Greater Risks with Long COVID

    August 20, 2024

    Subscribe to News

    Get the latest sports news from NewsSite about world, sports and politics.

    Editor's Picks

    Updates on Kate Middleton’s Cancer Journey

    September 16, 2024

    Healthcare communities unite at IHH Singapore Sea Regatta

    September 14, 2024

    Researchers Unveil Speech Clues to Dementia

    September 13, 2024

    The Lifeline of Trauma Care and Its Message For Road Safety

    September 13, 2024
    Latest Posts
    Advertisement
    Demo
    Facebook X (Twitter) Pinterest Vimeo WhatsApp TikTok Instagram

    News

    • World
    • US Politics
    • EU Politics
    • Business
    • Opinions
    • Connections
    • Science

    Company

    • Information
    • Advertising
    • Classified Ads
    • Contact Info
    • Do Not Sell Data
    • GDPR Policy
    • Media Kits

    Services

    • Subscriptions
    • Customer Support
    • Bulk Packages
    • Newsletters
    • Sponsored News
    • Work With Us

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    © 2025 ThemeSphere. Designed by ThemeSphere.
    • Privacy Policy
    • Terms
    • Accessibility

    Type above and press Enter to search. Press Esc to cancel.